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Abstract
Background: One-third of people with cancer experience psychological distress and may suppress distressing thoughts,
emotions, and concerns, leading to further problems. Conventional psychological treatments reduce distress by problem
solving, but in advanced cancer, when ill health is progressive and death may be approaching, physical and
psychological difficulties are complex and have no simple solutions. Acceptance and Commitment Therapy
encourages acknowledgement and acceptance of mental experiences, increasing people’s ability to work with problems
that cannot be solved. Previous pilot work in advanced cancer confirms that distress can be associated with an avoidance
of experiencing uncomfortable thoughts and emotions.
Methods/Design: This feasibility randomised controlled trial of Acceptance Commitment Therapy aims to establish
parameters for a larger trial. Fifty-four participants with advanced cancer will be randomly allocated to up to eight
sessions (each 1 hour) of Acceptance Commitment Therapy or a talking control. Participants will be recruited from
those attending outpatient services and hospice day care at three specialist palliative care units in North and East
London, United Kingdom. The primary outcome is a measure of functioning in four areas of life (physical, social/family,
emotional, and general activity) using the Functional Assessment of Cancer Therapies - General questionnaire at 3
months after randomisation. Secondary outcomes are (i) acceptance using the Acceptance and Action Questionnaire;
(ii) psychological distress using the Kessler Psychological Distress Scale; (iii) physical functioning using a timed walk and
sit-to-stand test; and (iv) quality of life measures including the Euroqol-5 Dimensions and ICECAP Supportive Care
measures. Qualitative data will be collected at 3 months to explore the participants’ experiences of the trial and
therapy. Data will be collected on the costs of care.
Discussion: Data generated on the recruitment, retention, and experience of the interventions and the usefulness of
the outcome measures will inform the adaptations required and whether changes in function are consistent with
existing data when planning for a sufficiently powered randomised controlled trial.
Trial registration: ISRCTN13841211 (registered 22 July 2015).
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Background
Patients with advanced cancer experience deterioration in
both physical and psychological functioning as their disease
progresses [35]. Palliative care aims to improve the quality
of life in the face of increasing symptom burden and dis-
ability [36]. Psychosocial interventions may be useful in
achieving improved quality of life [33] and the National In-
stitute of Health and Care Excellence recommends psycho-
logical interventions [29] in the treatment of psychological
distress in people with cancer. However, the intrusion of
negative thoughts or feelings associated with a deteriorat-
ing disease that may no longer be amenable to cure often
reduces the ability to address any social, psychological, or
spiritual problems [41]. New approaches are required to
support people to develop strategies to manage their nega-
tive emotions more effectively, especially when dealing
with life-threatening illness when problems often do not
have specific solutions.
Acceptance and Commitment Therapy (ACT) is a third
wave cognitive behavioural therapy (CBT). It is novel as it
encourages individuals to be willing to experience and
manage negative emotions and thoughts. Unlike conven-
tional CBT, ACT encourages psychological flexibility,
which enables people to manage their distress. Indeed,
avoidance of uncomfortable feelings (experiential avoid-
ance) may maintain psychological suffering [16]. Typically
delivered as a one-to-one process with a therapist, ACT
targets six core psychopathological processes by addressing
acceptance, cognitive diffusion, self as context, values, and
being present and committed action [18]. ACT may be par-
ticularly relevant in advanced cancer as it aims to encour-
age patients to tolerate problems and direct their
behaviours towards living in the present moment rather
than focussing on their fears for the future [20]. This may
be useful for those facing a limited prognosis and for whom
death is approaching. ACT does not encourage acceptance
of pain or discomfort that can be ameliorated by effective
medical treatments; rather it is about accepting the inevit-
ability of discomfort and physical limitation that can occur
in cancer and preventing the capacity for suffering.
ACT has been evaluated in a number of health-related
behavioural interventions [11, 14, 27, 42], and partici-
pants receiving ACT are more likely to report better
physical and psycho-social outcomes compared to those
receiving treatment as usual [32]. A recent review has
identified six studies using ACT in cancer settings,
which have provided useful pilot data but have been
methodologically limited, both in sample size and the
reporting of cancer stages [20]. No published studies
have evaluated the impact of ACT on improving both
psychological and physical functioning in patients specif-
ically with advanced cancer.
We began with preliminary work to understand the
relevance of ACT in advanced cancer. We conducted
a cross-sectional study of 101 people with advanced
cancer attending a specialist palliative care outpatient
unit to explore the relationship between experiential
acceptance (a preparedness to experience unpleasant
or unwelcome thoughts and emotions without strug-
gling to solve or resist them) and both psychological
morbidity and physical function [24]. We found that
those with high levels of experiential acceptance were
less likely to report psychological distress and have
improved physical function. This suggests that ACT
therapy to encourage experiential acceptance may be
of benefit in this population.
We now plan a phase II randomised controlled trial
(RCT) to determine the feasibility and acceptability of de-
livering an ACT intervention with people with advanced
cancer and obtain data to inform the conduct of a future
larger, definitive trial. We propose a two-arm trial, which
we have called CanACT, to compare ACT to a talking
control, and in which treatment as usual will be available
to all participants. The talking control intervention (TC;
[38]) has been developed to control for the main non-
specific factors that may operate in psychological talking-
based therapy. Expressing feelings in a therapeutic envir-
onment, rather than any specific aspect of ACT, may be
sufficient for improvement.
Although economic analyses in psycho-oncology are
infrequent [6], there is evidence to suggest psychologic-
ally based interventions lead to lower utilisation of
healthcare resources in cancer generally [34, 39, 43] and
in metastatic breast cancer [22].
In this paper, we report the protocol (version 8, 21
August 2015) for a two-arm feasibility randomised con-
trolled trial of the clinical and cost effectiveness of ACT
plus treatment as usual (TAU) compared to a talking
control (TC) plus TAU for people with advanced cancer
attending hospice ambulatory services.
We shall undertake the following tasks in this study:
1) Test the feasibility of recruitment to the trial,
retention and attrition.
2) Explore the feasibility of providing a therapist-
delivered intervention in this setting.
3) Assess the usefulness and acceptability of a range of
clinical and economic outcomes.
4) Assess if the data generated from the outcomes in
this trial support the conduct of a larger RCT.
5) Use qualitative methods to understand participants’
perceptions of whether ACT and TC are feasible and
acceptable interventions.
Methods/Design
Design
This is an exploratory, two parallel arm, randomised
controlled trial with a nested qualitative study.
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Setting
Recruitment of participants and implementation of the
intervention will take place in three specialist palliative
care day therapy units in North and East London,
United Kingdom (UK). Each unit serves diverse popula-
tions with a broad mix of ethnic and socio-economic
backgrounds representative of an inner city. All offer
hospice day care services consisting of a mixture of
medical-led, nurse-led and allied health professional-led
care. People may begin accessing these services either at
the end of active cancer treatments, during palliative
cancer treatments, or for symptom control in the ad-
vanced stages of their illness.
Support, funding and ethics
This trial is supported by the UCL PRIMENT Clinical Tri-
als Unit (https://www.ucl.ac.uk/priment). Funding for the
trial is provided by the National Institute for Health Re-
search (UK) through their Research for Patient Benefit
funding stream. Ethical approval has been obtained from
the London - Riverside Research Ethics Committee (14/
LO/0813). Local permission to conduct the study was
given by the following organisations: Marie Curie Hos-
pice Hampstead, St Joseph Hospice Hackney and the
Hospital of St John and St Elizabeth Ethics Committee.
All relevant parties will be informed about any import-
ant modifications to the protocol. The SPIRIT guide-
lines for this protocol are attached in the Additional file
1, highlighting which recommended items we have ad-
dressed in the reporting of this protocol.
Quantitative arm
Participants
We shall recruit 54 patients, with 27 in each arm. We
chose this number on pragmatic grounds because it is
sufficient to demonstrate feasibility in terms of recruit-
ment, acceptance of randomisation, and likely attrition.
Inclusion criteria
Eligible patients will meet the following criteria: i) aged >
18 years; ii) a clinical diagnosis of advanced cancer that
is not amenable to curative treatment (that is, those with
metastases at diagnosis, those at first or subsequent ex-
tensive recurrence, and those receiving palliative treat-
ments) and iii) exhibit a total score of < 81 on the
Functional Assessment of Cancer Therapies - General
(FACT-G). This score was selected as the mean score of
the FACT-G in a cancer population is 80.9 (SD 17.0) [5]
and depicts an important degree of dysfunction.
Exclusion criteria
Patients will be excluded if i) the clinician estimation of
patient survival is < 4 months; ii) the patient has insuffi-
cient command of English to engage in ACT or participate
in talking control; iii) the clinical or the research team
considers the patient to be cognitively impaired; or (iv)
the patient is currently receiving CBT (including ACT).
Recruitment process
The research team, together with clinic staff, will review
patient lists on a weekly basis. Clinicians will ask patients
identified as eligible to give initial consent to be involved
in the study. The research team will then complete the
FACT-G with patients who gave initial consent. A
researcher will give those scoring below the threshold of
81, verbal and written information about the study. These
patients will be given 48 hours to consider the study, after
which written informed consent for trial entry will be
obtained, baseline assessments will be collected, and
randomisation will occur.
Randomisation
Participants will be randomised to either ACT or the TC
group. Randomisation will be 1:1 to each treatment arm
and will be stratified by centre. Block randomisation with
varying block sizes will be used to recruit equal numbers
to each arm. The randomisation list is being generated by
PRIMENT CTU. The randomisation will be performed by
a senior member of the research team not connected with
either patient recruitment or data collection, who will
inform the therapists of the participants’ allocation. The
participants, the researcher collecting the data from trial
participants, and the trial statisticians will be masked to
the randomisation.
Interventions
There are two intervention arms: Acceptance Commit-
ment Therapy (ACT) and Talking Control (TC). For
both interventions, up to eight sessions (each 1 hour)
will be offered weekly and delivered within 3 months.
Sessions will usually take place face to face in a palliative
care day therapy unit but the final three may occur at
home if requested [37].
Acceptance Commitment Therapy
ACT is a contextual behavioural approach that uses a col-
lection of techniques aimed at increasing psychological
flexibility to change outcomes. Psychological flexibility is
the ability to persist in valued life activities alongside dis-
tressing or unwanted private events. There are two main
processes (i) mindfulness and acceptance (cognitive fusion
and self as context) and (ii) commitment and behaviour
change (being present, defining valued directions, and
committed action). We shall model the therapy on the
work of Hayes et al. [18] and supplement the approach
with the manual ‘Get out of your mind and into your life’
[17]. Therapists will be familiar with the skills training
manual ‘Learning act’ by Luoma et al. [27] and ‘ACT made
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simple’ by Harris [15] and have received training from the
Chief Investigator.
Talking control
TC promotes the use of common factors in therapy by
encouraging the therapist to be warm and welcoming,
allowing people to express their feelings, feel heard, and
understood. It specifically discourages focusing on prob-
lem areas and stipulates that problem solving should not
be attempted. The therapists are trained to adhere to
guidelines, and this approach has been used previously
to control for common factors in therapy [38].
Procedure
We shall collect baseline assessment measures from pa-
tients before they are randomised to either the ACT or TC
group. A senior member of the research team will notify
the therapists of the group allocation of participants. The
therapists will contact participants directly to arrange
therapeutic sessions. The research associate will approach
all participants face to face either in hospice outpatient set-
tings or in their homes (their preference) to collect follow-
up data to a maximum of 6 months post-baseline. At each
time point, we will offer each participant up to three op-
portunities to do the follow-ups. We shall also offer
follow-up by telephone if necessary to minimise attrition
and missing data, as participants may become increasingly
unwell during the study. A research associate specifically
employed for this study will conduct the assessments.
Table 1 summarises the assessment schedule. Although
participants and therapists cannot remain masked to
treatment group, the research team (with exception of the
research nurse and the senior researcher – see qualitative
arm) will be masked. As a check on blindness, research
associates and will be asked to guess group allocation after
they have completed each final follow-up assessment.
Unmasking will not occur until databases are closed and
the main analysis has been completed.
Treatment fidelity
There will be five therapists delivering either one of the
two interventions across the three sites. The same ther-
apist will deliver both ACT and TC to reduce group dif-
ferences in non-specific factors (for example, warmth
and professionalism). Therapists will have a minimum of
two years’ experience in delivery of psychotherapy and
will be accredited with the British Association of Cogni-
tive Behavioural Psychotherapists. To standardise the
two interventions and to ensure that the two therapies
are kept strictly separate, all therapists will receive a
training manual detailing both interventions and 1.5
days of training provided by the Chief Investigator (MS).
To ensure treatment fidelity, a random sample of 1 in 10
audio-taped sessions will be selected and stratified ac-
cording to therapist and phase of the intervention (early,
mid or end) and rated for quality using: a) ACT - an
adapted form of the scale developed by Plumb and Vilar-
daga [31] to assess treatment integrity and b) TC - a
modified checklist [38] for supervision to check that TC
is being delivered. The Chief Investigator will discuss is-
sues relating to the delivery of therapy with any therapist
who is not consistent in their delivery of ACT or TC.
Table 1 Timing of data collection
Measures Baseline 1 ½ months
post baseline
Post-intervention
(3 months)
4 ½ months
post baseline
Follow-up
(6 months)
Functional Assessment of Cancer Therapy - General ✓ ✓ ✓ ✓ ✓
Kessler Psychological Distress Scale ✓ ✓ ✓
2 minute walking test ✓ ✓ ✓
1 minute sit to stand test ✓ ✓ ✓
Acceptance and Action Questionnaire-II ✓ ✓ ✓
Value Living Questionnaire ✓ ✓ ✓
EQ5-D ✓ ✓ ✓
ICECAP supportive care measure ✓ ✓ ✓
Client Service Receipt Inventory ✓ ✓ ✓
Satisfaction with care ✓
Counselling questionnaire ✓
Expectation of therapy ✓
Treatment preference ✓
Assessment of blindness ✓ ✓
Attrition ✓ ✓
Other therapies used ✓ ✓
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Measures
Data on all measures will be recorded at baseline, 3
months (post-intervention) and 6 months. The FACT-G
will additionally be recorded at 1.5 months and 4.5
months to take into account the poor health of the pa-
tient group (15 % may die by the 6-month follow up
[24]) and allow maximal inclusion of data from all par-
ticipants for our main outcome measure. Demographic
data will be recorded at baseline only.
Demographic data
The following will be recorded from each participant:
age, gender, ethnicity, marital status, education, previous
psychiatric history, type of cancer and when diagnosed,
and the occupation of the main salaried person in the
household before retirement.
Patient functioning
Functional Assessment of Cancer Therapies – General
(FACT-G) (Version 4; [7]) is the main primary outcome,
as its four wellbeing domains (physical, social/family,
emotional, and activity) best reflect the main goals of
ACT. With high internal consistency reliability and val-
idity, it is recommended for assessing health-related
quality of life in advanced cancer [25]. Pilot work has
suggested that this measure is acceptable to use for our
population.
Psychological distress
The Kessler Psychological Distress Scale (K10; [21]), a
short self-report measure will be used to assess psycho-
logical distress. This measure was used in our prelimin-
ary study [25].
Physical functioning
Two measures will be used to evaluate physical function-
ing, as recommended by specialist physiotherapists work-
ing in cancer palliative care. These are the two minute
walking test (that is, the distance walked in 2 minutes in a
controlled space, at own speed, using an aid if necessary)
and the 1 minute sit to stand test (that is, the number of
times a person can stand up and sit down from a standar-
dised chair over 1 minute [23, 30]). Both measures were
used in our preliminary study (Low et al. [25]).
Process of ACT
Two measures will be used to evaluate two different
processes of ACT. The Acceptance and Action Ques-
tionnaire II (AAQII; [2]) will measure experiential
avoidance and participants’ willingness to accept
undesirable thoughts and feelings, whilst acting in
congruence with personal values and goals. This
measure was used in our preliminary work [25]. The
Valued Living Questionnaire (VLQ; [44]) will measure
how consistent their actions are with the values they
consider are important.
Economic
The following three economic measures will be used: i)
the EQ-5D ([4, 12]), a commonly used generic utility
measure of quality of life; ii) ICECAP supportive care
measure (ICECAP-SCM; [9]), a seven item capability
index specifically developed for assessment of people with
supportive and palliative care needs; and iii) short modi-
fied version of the Client Services Receipt Inventory
(CSRI, [1]) to collect service use of participant. We are
using both the EQ-5D and ICECAP-SCM in order to de-
termine the most appropriate health-related quality of life
measure for use in a larger trial.
Expectation, experience and satisfaction of therapy
At baseline, participants will be asked to assess their ex-
pectation of therapy using a single question [3], and
their treatment preference, using two questions [37]. At
3 months, participants will be asked to assess their ex-
perience of therapy, using a shortened version of the
Counselling Questionnaire [10], and a self-constructed
five-item questionnaire to rate their satisfaction with
therapy.
Assessment of blindness
The researcher undertaking the assessments will be
asked to guess trial arm allocation for each participant
after final follow-up.
Attrition
Dropout from therapy and reasons for not attending
therapy sessions will be recorded, along with loss to
follow-up (for example, dislike of therapy, deteriorating
health, and death).
Other therapies used
Participants’ medical notes will be accessed to obtain the
information on important covariates: (a) prescribed medi-
cations including the dose and changes in prescribed anal-
gesic and psychotropic medication; (b) other psychological
therapies offered as part of treatment as usual, which will
include any psychological intervention received during the
trial (for example, hypnotherapy, art therapy, counselling,
CBT, spiritual healing, or relaxation); (c) complementary
therapies received during the trial (for example, aroma-
therapy, massage, Reiki, reflexology, and herbal remedies);
and (d) gym and physical therapies.
Data analysis
Given this is a feasibility randomised trial, our main ana-
lysis will proceed as follows. We shall examine the numbers
of eligible patients, the recruitment rate, loss to follow-up,
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and adherence to therapy in both arms descriptively. We
shall determine, through completion rates, the appropriate-
ness and acceptability of the outcome measures. Our pri-
mary outcome is the FACT-G score measured at 3 months
follow-up because, at this point, we anticipate that partici-
pants will have completed their therapy, and the majority
will remain well enough for full data collection. Patient
characteristics will be summarised by trial arm using mean
(SD), median (interquartile ranges) or proportions as
appropriate. We shall estimate the intervention effect with
95 % confidence intervals using linear regression adjusted
for baseline values of FACT-G score and centre or suitable
alternatives in case of non-normally distributed data. This
will inform the sample size calculation for a main trial. We
will use regression models that account for clustering to
examine how the repeated measures of FACT-G score vary
over time. Analysis will be carried out on an intention to
treat basis. We will use the feasibility study results to exam-
ine therapist clustering descriptively. We will also conduct
a preliminary economic analysis.
We anticipate that 45 patients will complete the trial,
assuming 15 % attrition [24]. We shall examine the char-
acteristics of participants who drop out of each trial arm
and the reasons for attrition when available. This will
help us to understand the pattern of missing data and to
make appropriate plans to handle these missing data in
a larger scale RCT. All analyses will be performed using
Stata 13 or above [40].
Qualitative arm
A nested qualitative arm is incorporated into this trial
for a richer description of the patient experience of
receiving ACT or TC. A purposive sample of 20 partici-
pants at 3 months post-baseline will be invited to take
part in qualitative interviews to understand experiences
of therapy. In selecting participants, we shall to take
into account the allocated treatment, severity of illness,
gender, age, and ethnicity. The interviews, conducted
by the research nurse, will explore what participants
found helpful or unhelpful, any alterations in behaviour,
the experience of working with the therapist, any
factors that might inhibit the use of either ACT or TC
and what might contribute to non-engagement with
therapy, including potential reasons for withdrawal
from therapy and from this study. Interviews will be
transcribed verbatim and imported into NVIVO v10
(QSR) [29]. Two members of the research team (the re-
search nurse and a researcher) will independently read
the transcripts in-depth and using thematic content
analysis [13] extract emerging themes. Any disagree-
ments will be resolved by consensus. We shall explore
how themes are linked and whether variables such as
age, gender, ethnicity, severity of illness or perceptions
of therapy exert an effect.
Discussion
In this feasibility trial, we shall determine the feasibil-
ity of recruiting patients with advanced cancer to a
randomised controlled trial of ACT versus TC in this
setting. This will include follow-up rates, attrition and
outcome measures to inform the design of a larger
trial. Although we cannot at this stage test the effect-
iveness of this therapy, we shall learn whether it is
acceptable to people attending hospice outpatient
services. Our quantitative data will also provide an
initial understanding of the potential for benefit of
ACT for people facing advanced cancer and death.
Our qualitative data will increase our understanding of
the experience of receiving both ACT and TC sessions, in
particular which elements of the interventions are most
valued by participants.
Since participants are likely to experience clinical
deterioration as their disease progresses during the
study period, our trial is designed to allow flexible
options for delivery of the therapies and for follow-up
assessments. Participants will be contacted up to four
times, either by telephone or at a day hospice
appointment, to arrange the follow-up appointments.
It will be important to retain as many participants in
the trial for as long as possible, in particular because
it may be that the impact of the ACT interventions
become more relevant as health deteriorates, particu-
larly as attempting to restore function through prob-
lem solving will not be possible.
We have incorporated health economic assessments,
recognising that economic evaluation is an important
component of any interventional study as providers of
healthcare require an evidence base to ensure that
resources are used wisely. Should this study demon-
strate the feasibility of ACT as an intervention, we
would proceed to a fully powered RCT, the design of
which would be informed in part by the proposed
value of information analysis [13, 16] . Value of infor-
mation analysis is increasingly part of the standard
methodology of health economists. Within a full trial, a
comprehensive set of resource use data would be required
to evaluate the cost-effectiveness of the intervention.
The CanACT study is the first controlled trial to
evaluate individual ACT compared to a talking con-
trol, for treating people with advanced cancer and
dysfunction. The mixed methods used will help gener-
ate preliminary guidelines on how ACT may best be
delivered. If ACT appears beneficial, then this will
help generate preliminary guidelines that support the
use of ACT in an advanced cancer population. In the
medium term, findings will indicate whether or not a
fully powered RCT is feasible. If ACT proved to be cost-
effective in such a trial, it could become one of the recom-
mended treatments for palliative care patients. This could
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be delivered either through specialist palliative care ser-
vices or through the IAPT programme, whose goal is to
also treat longer term conditions [11], and which may be
adapted to treat people with cancer. We will also
disseminate the results of the study in international
journals and conferences.
Confidentiality
All study participants will be allocated a unique study ID
number for all written and electronic study data. All
study data will be fully anonymised and any personal
identifiable demographic information will be kept separ-
ately from the research results. All electronic records
will be password protected. All paper records will be
securely locked in a filing cabinet after use. In protecting
participants’ confidentiality (potential and enrolled), the
research team will abide by the regulations set in the
United Kingdom Data Protection Act 1998.
Trial status
A Research Associate responsible for patient recruitment
has been engaged since May 2015.
Patient recruitment will commence in October 2015.
Additional file
Additional file 1: ACT protocol paper SPIRIT 2013 Checklist (2015
09 30). File outlining how this protocol paper meets the different
guidelines from the SPIRIT 2013 Checklist. (DOCX 22 kb)
Abbreviations
AAQ-II: Acceptance and Action Questionnaire II; ACT: Acceptance and
Commitment Therapy; CBT: Cognitive Behavioural Therapy; EQ-5D: Euroqol-5D;
FACT-G: Functional Assessment of Cancer Therapies – General; K-10: Kessler
Psychological Distress Scale; RCT: Randomised Control Trial; TAU: Treatment As
Usual; TC: Talking control; VLQ: Valued Living Questionnaire.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JL conceived the study, contributed to the study design, obtained grant
funding, and was responsible for preparing the manuscript. MS conceived
the study, contributed to the study design, obtained grant funding, revised
the manuscript and is the Chief Investigator. SD, VV, LJ, MK, AT, KT conceived
the study, contributed to the study design, obtained grant funding, and
revised the manuscript. RZO, JStJA, AG contributed to the study design,
obtained grant funding, and revised the manuscript. All authors read and
approved the final version.
Acknowledgements
We would like to acknowledge the following: the National Institute for Health
Research, Research for Patient Benefit for funding the study (RfPB: PB-PG-1111-
26043); Marie Curie for funding the Research Department where JL, SD, LJ, VV
and AG are based; Camden and Islington NHS Foundation Trust for acting as
sponsors for the study; Dr Libby Sallnow (St Joseph’s Hospice Hackney), Dr Faye
Gishen (Marie Curie Hospice Hampstead) and Ms Sue Hutton (St John’s Hospice)
for their support in setting up the study in their respective centres; and Dr Megan
Armstrong, Research Associate for CanACT, for proof reading this article.
Author details
1Marie Curie Palliative Care Research Department, Division of Psychiatry,
University College London, 6th Floor, Maple House, 149 Tottenham Court
Road, London W1T 7NF, UK. 2Division of Psychiatry, University College
London, 6th Floor, Maple House, 149 Tottenham Court Road, London W1T
7NF, UK. 3Department of Statistical Science, University College London, 1-19
Torrington Place, London WC1E 7HB, UK. 4Marie Curie Hospice Hampstead,
11 Lyndhurst Gardens, London NW3 5NS, UK. 5PPI Representative, London,
UK.
Received: 6 October 2015 Accepted: 12 January 2016
References
1. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G,
Brewin C, Wing J, editors. Measuring mental health needs. London: Gaskill;
1992. p. 179–90.
2. Bond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, et al.
Preliminary psychometric properties of the Acceptance and Action
Questionnaire – II: A revised measure of psychological inflexibility and
experiential avoidance. Behav Ther. 2011;42:676–88.
3. Borkovec TD, Nau SD. Credibility of analogue therapy rationales. J Behav
Ther Exp Psychiatry. 1972;3:257–60.
4. Brooks R. EuroQoL: the current state of play. Health Policy. 1996;37:53–72.
5. Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and
cancer patient norms for the Functional Assessment of Cancer Therapy -
General (FACT-G). Eval Health Prof. 2005;28:192–211.
6. Carlson LE, Bultz BD. Efficacy and medical cost offset of psychosocial
interventions in cancer care: making a case for economic analyses.
Psychooncology. 2004;13:837–49.
7. Cella DF, Tulsky DS, Gray G, Sarafian B, Lloyd S, Linn E, et al. The Functional
assessment of Cancer Therapy Scale: development and validation of the
general measure. J Clin Oncol. 1993;11:570–9.
8. Coast J, Peters T, Natarajan L, Sproston K, Flynn T. An assessment of the
construct validity of the descriptive system for the ICECAP capability
measure for older people. Qual Life Res. 2008;17:967–76.
9. Corney R. Evaluating clinical counselling in primary care and the future. In:
Lees J, editor. Clinical counselling in primary care. London: Routledge; 1999.
10. Dahl J, Wilson KG, Nilsson A. Acceptance and Commitment Therapy and
the treatment ofpersons at risk for long-term disability resulting from
stress and pain symptoms: a preliminary randomized trial. Behav Ther.
2004;35:785–801.
11. Department of Health. IAPT Implementation Plan: National guidelines
for regional delivery. 2008. www.iapt.nhs.uk/silo/files/implementation-
plan-national-guidelines-for-regional-delivery.pdf. Accessed date 16
January 2016.
12. EuroQoL group. EuroQol - a new facility for the measurement of
health-related quality of life. Health Policy. 1990;16:199–208.
13. Fenwick E, Claxton K, Sculpher M. The value of implementation and the
value of information: combined and uneven development. Medical
Decision Making. 2008;28(1):21–32.
14. Green J, Thorogood N. Qualitative methods for health research. Los
Angeles, London, New Delhi, Singapore, Washington DC: SAGE
Publication Second Edition; 2009.
15. Gregg JA, Callaghan GM, Hayes SC, Glenn-Lawson JL. Improving diabetes
self-management through acceptance, mindfulness, and values: a
randomized controlled trial. J Consult Clin Psychol. 2007;2007(75):336–43.
16. Hall PS, Edlin R, Kharroubi S, Gregory W, McCabe C. Expected net present
value of sample information: from burden to investment. Medical Decision
Making. 2012;32(3):E11–21.
17. Harris R. ACT made simple: an easy to read primer on Acceptance and
Commitment Therapy. Oakland, CA: New Harbinger Publications; 2009.
18. Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy:
An experiential approach to behaviour change. New York London: The
Guildford Press; 1999.
19. Hayes SC, Smith S. Get out of your mind and into your life: The new
Acceptance and Commitment Therapy. Oakland CA: New Harbinger; 2005.
20. Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and
Committment Therapy: Model, process and outcomes. Behav Res Ther.
2006;44:1–25.
Low et al. Trials  (2016) 17:77 Page 7 of 8
21. Hulbert-Williams NJ, Storey L, Wilson KG. Psychological interventions for
patients with cancer: psychological flexibility and the potential utility of
Acceptance and Commitment Therapy. Eur J Cancer Care. 2015;24:15–27.
22. Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, Hiripi E, et al.
Screening for serious mental illness in the general population. Arch Gen
Psychiatry. 2003;60:184–9.
23. Lemieux J, Topp A, Chappell H, Ennis M, Goodwin J. Economic analysis of
psychosocial group therapy in women with metastatic breast cancer. Breast
Cancer Res Treat. 2006;100:183–90.
24. Leung ASY, Chan KK, Sykes K, Chan KS. Reliability, validity, and
responsiveness of a 2-min walk test to assess exercise capacity of COPD
patients. Chest. 2006;130:119–25.
25. Low J, Davis S, Drake R, King M, Tookman A, Turner A, et al. The role of
acceptance in rehabilitation in life threatening illness. J Pain Symptom
Manage. 2012;43:20–8.
26. Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MP, et al.
Choosing between the EORTC QLQ-C30 and FACT-G for measuring
health-related quality of life. Ann Oncol. 2011;22:2179–90.
27. Luoma JB, Hayes SC, Walser RD, Learning ACT. An Acceptance &
Commitment therapy skills training manual for therapists. Oakland CA: New
Harbinger; 2005.
28. McCracken LM, Vowles KE, Eccleston C. Acceptance-based treatment for
persons with complex, long standing chronic pain: a preliminary analysis of
treatment outcome in comparison to a waiting phase. Behav Res Ther.
2005;43:1335–46.
29. National Institute of Clinical Excellence. Guidance on Cancer. Improving
Supportive and Palliative Care for Adults with Cancer. https://www.nice.org.
uk/guidance/csg4. Accessed date 19 January 2016.
30. NVivo qualitative data analysis software; QSR International Pty Ltd. Version
10, 2012.
31. Oldervoll LM, Loge JH, Paltiel H, Asp MB, Vidvei U, Wiken AN, et al. The
effect of a physical exercise program in palliative care: A phase II study.
J Pain Symptom Manage. 2006;31:421–30.
32. Plumb J, Vilardaga R. Assessing Treatment Integrity in Acceptance and
Commitment Therapy: Strategies and Suggestions. International Journal of
Behavioral Consultation and Therapy. 2010;6:264–95.
33. Powers MB, Vording MBZVS, Emmelkamp PMG. Acceptance and Commitment:
A meta-analytic review. Psychother Psychosom. 2009;78:73–80.
34. Rehse B, Pukrop R. Effects of psychosocial interventions on quality of life in
adult cancer patients: meta analysis of 37 published controlled outcome
studies. Patient Educ Couns. 2003;50:179–86.
35. Rosenberg HJ, Rosenberg SD, Ernstoff MS, Wolford GL, Amdur RJ, Elshamy MR,
et al. Expressive disclosure and health outcomes in a prostate cancer
population. Int J Psychiatry Med. 2002;32:37–53.
36. Santiago-Palma J, Payne R. Palliative care and rehabilitation. Cancer.
2001;92 Suppl 4:1049–52.
37. Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative care: The World Health
Organisation’s global perspective. J Pain Symptom Manage. 2002;24:91–6.
38. Serfaty MA, Haworth D, Blanchard M, Buszewicz M, Murad S, King M. Clinical
effectiveness of cognitive behaviour therapy, versus control treatment or
treatment as usual for depressed older people in general practice. Arch Gen
Psychiatry. 2009;66:1332–40.
39. Serfaty MA, Csipke E, Howarth D, Murad S, King M. A Talking Control for use
in evaluating the effectiveness of Cognitive Behavioral Therapy. Behav Res
Ther. 2011;49:433–40.
40. Simpson JS, Carlson LE, Trew ME. Effect of group therapy for breast cancer
on healthcare utilization. Cancer Pract. 2001;9:19–26.
41. StataCorp. Stata Statistical Software: Release 13. College Station:
StataCorp LP; 2013.
42. Tookman AJ, Hopkins KF. Rehabilitation and specialist palliative care.
Int J Palliat Nurs. 2001;6:123–30.
43. Wicksell RK, Olsson GL, Hayes SC. Psychological flexibility as a mediator of
improvement in Acceptance and Commitment Therapy for patients with
chronic pain following whiplash. Eur J Pain. 2010;14:1059. e1-1059.e11.
44. Wiles N, Thomas L, Abel A, Barnes M, Carroll F, Ridgway N, et al. Clinical
effectiveness and cost-effectiveness of cognitive behavioural therapy as an
adjunct to pharmacotherapy for treatment-resistant depression in primary care:
the CoBalT randomised controlled trial. Health Technol Assess. 2014;18:1–167.
45. Wilson KG, Sandoz EK, Kitchens J. The Valued Living Questionnaire: Defining
and Measuring Valued Action within a Behavioral Framework. Psychol Rec.
2010;60:249–72.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Low et al. Trials  (2016) 17:77 Page 8 of 8
